Zobrazeno 1 - 10
of 120
pro vyhledávání: '"Martin, Ruthardt"'
Autor:
Ecmel Mehmetbeyoglu, Claudia Chiriches, Imran Shair Mohammed, Beyza Nur Onat, Kadir Yaray, Oguz Galip Yildiz, Serpil Taheri, Martin Ruthardt
Publikováno v:
HemaSphere, Vol 7, p e69134db (2023)
Externí odkaz:
https://doaj.org/article/61ee5b602f77466f98220b3674253c2e
Publikováno v:
HemaSphere, Vol 7, p e93079e9 (2023)
Externí odkaz:
https://doaj.org/article/4171f44dcfd34a51a5c9c8b1c447eeff
Autor:
Claudia Chiriches, Nathalie Nicolaisen, Maria Wieske, Heba Elhaddad, Ecmel Mehmetbeyoglu, Caroline Alvares, Dörte Becher, Paul Hole, Oliver Gerhard Ottmann, Martin Ruthardt
Publikováno v:
PLoS Genetics, Vol 18, Iss 10, p e1010463 (2022)
The WHO classifies t(6;9)-positive acute myeloid leukemia (AML) as a subgroup of high-risk AML because of its clinical and biological peculiarities, such as young age and therapy resistance. t(6;9) encodes the DEK/NUP214 fusion oncoprotein that targe
Externí odkaz:
https://doaj.org/article/b9784da331f645fe9b92d4e7d5409c3f
Autor:
Elif Tugce Sarcan, Stephen Paisey, Martin Ruthardt, Asuman Yekta Ozer, Christopher Marshall, Neil Hartman
Publikováno v:
Journal of Radioanalytical and Nuclear Chemistry. 331:5507-5516
Autor:
Martin Ruthardt, Thorsten J. Maier, Ingrid Fleming, Dieter Steinhilber, Elena Puccetti, Ewgenij Proschak, Estel la Buscató, Ricardo Capelo, Astrid S. Kahnt, Hannelore Held, Dilawar Khan, Maria Heinssmann, Claudia Oancea, Jessica Roos
Pharmaceutical inhibition of all three major arachidonic acid pathways and its effect on replating efficiency of PML/RARα-expressing murine HSPCs.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f4d186128e45ea2be2482d464306569
https://doi.org/10.1158/0008-5472.22402526
https://doi.org/10.1158/0008-5472.22402526
Autor:
Martin Ruthardt, Thorsten J. Maier, Ingrid Fleming, Dieter Steinhilber, Elena Puccetti, Ewgenij Proschak, Estel la Buscató, Ricardo Capelo, Astrid S. Kahnt, Hannelore Held, Dilawar Khan, Maria Heinssmann, Claudia Oancea, Jessica Roos
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::730d460ead21cc103ab6a56ed605cc46
https://doi.org/10.1158/0008-5472.22402529.v1
https://doi.org/10.1158/0008-5472.22402529.v1
Autor:
Claudia Chiriches, Dilawar Khan, Maria Wieske, Nathalie Guillen, Michal Rokicki, Carol Guy, Marieangela Wilson, Kate J. Heesom, Oliver Gerhard Ottmann, Martin Ruthardt
Patients within the WHO-subgroup of t(6;9)-positive acute myeloid leukemia (AML) differ from other AML subgroups as they are characterised by younger age and a grim prognosis. Leukemic transformation can often be attributed to single chromosomal aber
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62c32fa14515f5be58a1c40634745b85
https://orca.cardiff.ac.uk/id/eprint/151862/1/Chiriches2022_Article_ActivationOfSignalingPathwaysI.pdf
https://orca.cardiff.ac.uk/id/eprint/151862/1/Chiriches2022_Article_ActivationOfSignalingPathwaysI.pdf
Publikováno v:
Archives of Medical Science : AMS
Autor:
Anahita Rafiei, Afsar Ali Mian, Claudia Döring, Anna Metodieva, Claudia Oancea, Frederic B Thalheimer, Martin Leo Hansmann, Oliver Gerhard Ottmann, Martin Ruthardt
Publikováno v:
PLoS Genetics, Vol 11, Iss 4, p e1005144 (2015)
The hallmark of Philadelphia chromosome positive (Ph(+)) leukemia is the BCR/ABL kinase, which is successfully targeted by selective ATP competitors. However, inhibition of BCR/ABL alone is unable to eradicate Ph(+) leukemia. The t(9;22) is a recipro
Externí odkaz:
https://doaj.org/article/e656123223284eafa41f1d7b430b3911